Edition:
United Kingdom

Deena Beasley

Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.

Twitter handle: @jeffmason1

17 Nov 2017

Trump administration proposes Medicare rules aimed at opioids, drug costs

The Trump administration on Thursday proposed changes to Medicare drug plans including limits on opioid prescriptions and rules aimed at reducing drug costs for seniors, such as requiring health insurers to pass on discounts to consumers.

14 Nov 2017

New blood pressure range means half of Americans have hypertension

Tighter blood pressure guidelines from U.S. heart organizations mean millions more people need to make lifestyle changes, or start taking medication, in order to avoid cardiovascular problems.

13 Nov 2017

New blood pressure range means nearly half of Americans have hypertension

Nov 13 Tighter blood pressure guidelines from U.S. heart organizations mean millions more people need to make lifestyle changes, or start taking medication, in order to avoid cardiovascular problems.

26 Oct 2017

Gilead weak hepatitis C sales outlook sends shares lower

Gilead Sciences Inc posted better-than-expected third-quarter profit on Thursday, but shares fell after hours as use of its flagship hepatitis C drugs waned further and the company said it expects to feel the full impact of more competition in the current quarter.

26 Oct 2017

Gilead 3rd-quarter profit falls, but beats Wall Street estimates

Oct 26 Gilead Sciences Inc reported lower third-quarter profits on Thursday as use of its flagship hepatitis C drugs continued to wane, but the results beat Wall Street estimates due to lower costs.

26 Oct 2017

Bristol-Myers sales in line, but profit margins worsen

Bristol-Myers Squibb Co reported a 7 percent increase in third-quarter revenue as sales of key drugs met Wall Street expectations, but earnings fell short due to higher costs and an inventory write-off, sending shares down 4 percent.

26 Oct 2017

Bristol Myers posts in-line sales, but profit margins worsen

Oct 26 Bristol-Myers Squibb Co reported a 7 percent increase in third-quarter revenue as sales of key drugs met Wall Street expectations, but adjusted earnings fell slightly short due to an inventory write-off.

25 Oct 2017

Vertex ups cystic fibrosis sales view, but 2 trials fail

Vertex Pharmaceuticals Inc raised its outlook for full-year sales of its cystic fibrosis drugs as it released quarterly earnings on Wednesday, but the company reported disappointing results from two clinical trials and its shares tumbled 3 percent in after-hours trade.

20 Oct 2017

Merck to cut 1,800 U.S. sales jobs, add 960 in chronic care

Drugmaker Merck & Co Inc , moving to a new sales team structure in the United States, plans to cut 1,800 sales positions, while adding 960 jobs to a new chronic care sales force, the company said on Friday.

04 Oct 2017

Cigna to end OxyContin painkiller coverage, signs contract for alternative

Amid a growing U.S. opioid addiction, health insurer Cigna Corp will stop covering OxyContin, the opioid painkiller sold by Purdue Pharma LP, as of Jan. 1 and will instead cover an equivalent with a formulation less vulnerable to abuse, the company said on Wednesday.

  • Europe
  • U.S.
  • Asia
  • Sectors
Stock Search
FTSE 100 7,380.68 -6.26 -0.08%
DAX 12,993.73 -53.49 -0.41%
CAC 40 5,319.17 -17.22 -0.32%
TR Europe 182.00 -0.13 -0.07%
GBP/USD 1.3211 +0.00%
GBP/EUR 1.1199 +0.00%
EUR/USD 1.1793 +0.00%
Gold 1,288.30 +10.80 +0.85%
Oil 56.68 +1.54 +2.79%
Corn 343.25 +6.75 +2.01%